Stem definition | Drug id | CAS RN |
---|---|---|
antivirals | 989 | 154598-52-4 |
Dose | Unit | Route |
---|---|---|
0.60 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.01 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 27.15 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 42.50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 17, 1998 | FDA | BRISTOL MYERS SQUIBB |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Abortion spontaneous | 642.33 | 25.03 | 248 | 8403 | 41524 | 50554949 |
Viral mutation identified | 560.66 | 25.03 | 112 | 8539 | 1517 | 50594956 |
Maternal exposure during pregnancy | 555.50 | 25.03 | 342 | 8309 | 159436 | 50437037 |
Virologic failure | 505.17 | 25.03 | 102 | 8549 | 1462 | 50595011 |
Pregnancy | 434.22 | 25.03 | 170 | 8481 | 29407 | 50567066 |
Abortion induced | 426.86 | 25.03 | 126 | 8525 | 9218 | 50587255 |
Immune reconstitution inflammatory syndrome | 386.68 | 25.03 | 104 | 8547 | 5412 | 50591061 |
Exposure during pregnancy | 374.24 | 25.03 | 241 | 8410 | 120774 | 50475699 |
Stillbirth | 374.21 | 25.03 | 103 | 8548 | 5849 | 50590624 |
Drug resistance | 299.23 | 25.03 | 115 | 8536 | 18874 | 50577599 |
Normal newborn | 261.32 | 25.03 | 80 | 8571 | 6611 | 50589862 |
Pathogen resistance | 260.93 | 25.03 | 77 | 8574 | 5612 | 50590861 |
Foetal exposure during pregnancy | 233.21 | 25.03 | 107 | 8544 | 27252 | 50569221 |
Blood HIV RNA increased | 172.41 | 25.03 | 35 | 8616 | 514 | 50595959 |
Lipodystrophy acquired | 167.15 | 25.03 | 40 | 8611 | 1289 | 50595184 |
Live birth | 151.84 | 25.03 | 68 | 8583 | 16340 | 50580133 |
Caesarean section | 126.41 | 25.03 | 59 | 8592 | 15580 | 50580893 |
Premature delivery | 108.75 | 25.03 | 61 | 8590 | 23602 | 50572871 |
Birth mark | 94.90 | 25.03 | 17 | 8634 | 121 | 50596352 |
Viral load increased | 91.27 | 25.03 | 24 | 8627 | 1139 | 50595334 |
Cerebellar ataxia | 87.90 | 25.03 | 22 | 8629 | 856 | 50595617 |
Lactic acidosis | 87.08 | 25.03 | 60 | 8591 | 33295 | 50563178 |
Pregnancy with implant contraceptive | 86.70 | 25.03 | 26 | 8625 | 1997 | 50594476 |
Congenital umbilical hernia | 81.01 | 25.03 | 17 | 8634 | 296 | 50596177 |
Pregnancy on contraceptive | 79.17 | 25.03 | 21 | 8630 | 1031 | 50595442 |
Pulmonary tuberculosis | 78.54 | 25.03 | 29 | 8622 | 4244 | 50592229 |
Treatment noncompliance | 68.88 | 25.03 | 50 | 8601 | 30100 | 50566373 |
Fanconi syndrome acquired | 67.44 | 25.03 | 18 | 8633 | 905 | 50595568 |
Ectopic pregnancy | 54.88 | 25.03 | 19 | 8632 | 2308 | 50594165 |
Cleft lip and palate | 51.25 | 25.03 | 12 | 8639 | 351 | 50596122 |
Hepatitis fulminant | 49.75 | 25.03 | 19 | 8632 | 3049 | 50593424 |
Foetal death | 48.52 | 25.03 | 25 | 8626 | 8155 | 50588318 |
CD4 lymphocytes decreased | 47.98 | 25.03 | 15 | 8636 | 1324 | 50595149 |
Portal hypertension | 47.90 | 25.03 | 19 | 8632 | 3373 | 50593100 |
Autoimmune hepatitis | 47.56 | 25.03 | 24 | 8627 | 7495 | 50588978 |
Drug interaction | 47.43 | 25.03 | 105 | 8546 | 199516 | 50396957 |
Immune reconstitution inflammatory syndrome associated tuberculosis | 47 | 25.03 | 11 | 8640 | 321 | 50596152 |
Tuberculosis | 46.31 | 25.03 | 26 | 8625 | 10057 | 50586416 |
Malaria | 46.24 | 25.03 | 10 | 8641 | 202 | 50596271 |
Cholestatic liver injury | 45.73 | 25.03 | 16 | 8635 | 2005 | 50594468 |
Premature baby | 45.53 | 25.03 | 32 | 8619 | 18305 | 50578168 |
Pain | 42.74 | 25.03 | 23 | 8628 | 578880 | 50017593 |
Fatigue | 40.55 | 25.03 | 37 | 8614 | 707564 | 49888909 |
Nephropathy toxic | 40.43 | 25.03 | 22 | 8629 | 8007 | 50588466 |
Hepatomegaly | 39.45 | 25.03 | 24 | 8627 | 10769 | 50585704 |
Premature rupture of membranes | 39.23 | 25.03 | 18 | 8633 | 4562 | 50591911 |
Rash maculo-papular | 36.96 | 25.03 | 33 | 8618 | 26608 | 50569865 |
Anaemia | 35.40 | 25.03 | 109 | 8542 | 252347 | 50344126 |
Congenital anomaly | 34.25 | 25.03 | 12 | 8639 | 1509 | 50594964 |
Twin pregnancy | 33.83 | 25.03 | 11 | 8640 | 1102 | 50595371 |
Gene mutation | 32.39 | 25.03 | 11 | 8640 | 1260 | 50595213 |
Cardiac malposition | 32.24 | 25.03 | 6 | 8645 | 54 | 50596419 |
Maternal drugs affecting foetus | 31.51 | 25.03 | 16 | 8635 | 5061 | 50591412 |
Spinocerebellar disorder | 31.44 | 25.03 | 5 | 8646 | 15 | 50596458 |
Pregnancy on oral contraceptive | 31.29 | 25.03 | 10 | 8641 | 948 | 50595525 |
Pachygyria | 30.70 | 25.03 | 4 | 8647 | 0 | 50596473 |
Drug ineffective | 30.44 | 25.03 | 59 | 8592 | 819274 | 49777199 |
Arthralgia | 30.09 | 25.03 | 19 | 8632 | 438683 | 50157790 |
Pre-eclampsia | 29.68 | 25.03 | 18 | 8633 | 8026 | 50588447 |
Meningitis cryptococcal | 29.54 | 25.03 | 10 | 8641 | 1135 | 50595338 |
Retinal toxicity | 29.18 | 25.03 | 10 | 8641 | 1178 | 50595295 |
Hepatic displacement | 29.10 | 25.03 | 5 | 8646 | 27 | 50596446 |
Diastasis recti abdominis | 27.74 | 25.03 | 5 | 8646 | 37 | 50596436 |
Jaundice | 27.63 | 25.03 | 28 | 8623 | 26401 | 50570072 |
HIV-associated neurocognitive disorder | 27.57 | 25.03 | 6 | 8645 | 125 | 50596348 |
Isosporiasis | 27.39 | 25.03 | 5 | 8646 | 40 | 50596433 |
Polydactyly | 27.22 | 25.03 | 7 | 8644 | 304 | 50596169 |
Lipoatrophy | 27.17 | 25.03 | 7 | 8644 | 306 | 50596167 |
Cytomegalovirus chorioretinitis | 26.85 | 25.03 | 10 | 8641 | 1497 | 50594976 |
AIDS related complication | 26.65 | 25.03 | 4 | 8647 | 7 | 50596466 |
Hydrocephalus | 26.58 | 25.03 | 14 | 8637 | 4774 | 50591699 |
Type III hyperlipidaemia | 26.31 | 25.03 | 4 | 8647 | 8 | 50596465 |
Renal tubular disorder | 25.43 | 25.03 | 11 | 8640 | 2426 | 50594047 |
Multiple-drug resistance | 25.21 | 25.03 | 12 | 8639 | 3302 | 50593171 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Depression | 1116.33 | 16.25 | 675 | 17441 | 84472 | 29471939 |
Immune reconstitution inflammatory syndrome | 825.95 | 16.25 | 270 | 17846 | 7532 | 29548879 |
Drug interaction | 754.54 | 16.25 | 752 | 17364 | 196633 | 29359778 |
Virologic failure | 703.99 | 16.25 | 190 | 17926 | 2657 | 29553754 |
Viral mutation identified | 676.52 | 16.25 | 179 | 17937 | 2309 | 29554102 |
Lipodystrophy acquired | 574.62 | 16.25 | 165 | 17951 | 2929 | 29553482 |
Pathogen resistance | 489.95 | 16.25 | 185 | 17931 | 7931 | 29548480 |
Mitochondrial toxicity | 285.70 | 16.25 | 91 | 18025 | 2320 | 29554091 |
Progressive external ophthalmoplegia | 230.03 | 16.25 | 67 | 18049 | 1250 | 29555161 |
Drug resistance | 223.48 | 16.25 | 148 | 17968 | 21392 | 29535019 |
Loss of personal independence in daily activities | 214.89 | 16.25 | 154 | 17962 | 25286 | 29531125 |
Eyelid ptosis | 201.04 | 16.25 | 86 | 18030 | 5100 | 29551311 |
Lipoatrophy | 151.24 | 16.25 | 39 | 18077 | 450 | 29555961 |
Foetal exposure during pregnancy | 140.84 | 16.25 | 136 | 17980 | 33731 | 29522680 |
Psychiatric decompensation | 127.08 | 16.25 | 44 | 18072 | 1460 | 29554951 |
CD4 lymphocytes decreased | 120.68 | 16.25 | 43 | 18073 | 1555 | 29554856 |
Diplopia | 114.44 | 16.25 | 82 | 18034 | 13436 | 29542975 |
Abnormal dreams | 111.36 | 16.25 | 63 | 18053 | 6857 | 29549554 |
Depression suicidal | 109.29 | 16.25 | 38 | 18078 | 1277 | 29555134 |
Tearfulness | 104.84 | 16.25 | 39 | 18077 | 1597 | 29554814 |
Pulmonary tuberculosis | 99.71 | 16.25 | 50 | 18066 | 4265 | 29552146 |
Retinal toxicity | 95.28 | 16.25 | 26 | 18090 | 378 | 29556033 |
Treatment failure | 94.83 | 16.25 | 115 | 18001 | 36824 | 29519587 |
Hyperlipidaemia | 94.44 | 16.25 | 71 | 18045 | 12519 | 29543892 |
Blood HIV RNA increased | 82.83 | 16.25 | 29 | 18087 | 995 | 29555416 |
Viral load increased | 82.77 | 16.25 | 35 | 18081 | 2014 | 29554397 |
Paranoia | 79.23 | 16.25 | 58 | 18058 | 9819 | 29546592 |
Hyperlactacidaemia | 73.79 | 16.25 | 35 | 18081 | 2643 | 29553768 |
Kaposi's sarcoma | 71.98 | 16.25 | 25 | 18091 | 837 | 29555574 |
Gynaecomastia | 69.89 | 16.25 | 50 | 18066 | 8167 | 29548244 |
Fanconi syndrome acquired | 69.57 | 16.25 | 30 | 18086 | 1812 | 29554599 |
Off label use | 69.54 | 16.25 | 50 | 18066 | 300750 | 29255661 |
Hepatic fibrosis | 67.34 | 16.25 | 35 | 18081 | 3217 | 29553194 |
Renal tubular disorder | 63.02 | 16.25 | 37 | 18079 | 4315 | 29552096 |
Ophthalmoplegia | 62.23 | 16.25 | 27 | 18089 | 1655 | 29554756 |
Depressive symptom | 58.47 | 16.25 | 26 | 18090 | 1691 | 29554720 |
Fanconi syndrome | 57.00 | 16.25 | 25 | 18091 | 1573 | 29554838 |
Treatment noncompliance | 56.64 | 16.25 | 72 | 18044 | 24155 | 29532256 |
HIV-associated neurocognitive disorder | 54.69 | 16.25 | 16 | 18100 | 303 | 29556108 |
Meningitis cryptococcal | 53.47 | 16.25 | 26 | 18090 | 2074 | 29554337 |
Hypertriglyceridaemia | 51.31 | 16.25 | 40 | 18076 | 7435 | 29548976 |
Psychomotor skills impaired | 47.65 | 16.25 | 26 | 18090 | 2635 | 29553776 |
Immune reconstitution inflammatory syndrome associated tuberculosis | 46.57 | 16.25 | 15 | 18101 | 396 | 29556015 |
Death | 46.49 | 16.25 | 87 | 18029 | 341997 | 29214414 |
Psychotic disorder | 45.24 | 16.25 | 59 | 18057 | 20295 | 29536116 |
Pneumonia | 44.76 | 16.25 | 80 | 18036 | 320092 | 29236319 |
Multiple-drug resistance | 43.33 | 16.25 | 28 | 18088 | 3872 | 29552539 |
Nephropathy toxic | 42.42 | 16.25 | 42 | 18074 | 10714 | 29545697 |
Osteoporosis | 40.54 | 16.25 | 41 | 18075 | 10728 | 29545683 |
Fall | 40.13 | 16.25 | 30 | 18086 | 177148 | 29379263 |
Hepatitis | 39.74 | 16.25 | 56 | 18060 | 20727 | 29535684 |
Portal hypertension | 38.66 | 16.25 | 25 | 18091 | 3461 | 29552950 |
Nightmare | 38.54 | 16.25 | 41 | 18075 | 11376 | 29545035 |
Retroviral rebound syndrome | 38.19 | 16.25 | 7 | 18109 | 11 | 29556400 |
Febrile neutropenia | 37.69 | 16.25 | 11 | 18105 | 112229 | 29444182 |
Drug abuse | 37.62 | 16.25 | 3 | 18113 | 79880 | 29476531 |
Lymph node tuberculosis | 37.55 | 16.25 | 13 | 18103 | 431 | 29555980 |
Hydrocele | 37.54 | 16.25 | 20 | 18096 | 1933 | 29554478 |
Dyslipidaemia | 36.42 | 16.25 | 30 | 18086 | 6031 | 29550380 |
Renal impairment | 36.33 | 16.25 | 121 | 17995 | 81212 | 29475199 |
Tuberculosis | 35.86 | 16.25 | 32 | 18084 | 7164 | 29549247 |
Lymphadenopathy | 35.86 | 16.25 | 59 | 18057 | 24990 | 29531421 |
Hypotension | 35.60 | 16.25 | 40 | 18076 | 194314 | 29362097 |
Proteinuria | 35.41 | 16.25 | 46 | 18070 | 15758 | 29540653 |
Drug ineffective | 35.34 | 16.25 | 110 | 18006 | 363060 | 29193351 |
Fatigue | 35.22 | 16.25 | 90 | 18026 | 316731 | 29239680 |
Lactic acidosis | 35.17 | 16.25 | 65 | 18051 | 30182 | 29526229 |
Tuberculoid leprosy | 34.34 | 16.25 | 8 | 18108 | 58 | 29556353 |
Product dose omission issue | 33.18 | 16.25 | 9 | 18107 | 96374 | 29460037 |
Pain | 32.81 | 16.25 | 34 | 18082 | 171398 | 29385013 |
Atrial fibrillation | 32.57 | 16.25 | 12 | 18104 | 105634 | 29450777 |
Neurosyphilis | 32.11 | 16.25 | 7 | 18109 | 36 | 29556375 |
Mycobacterium avium complex infection | 32.09 | 16.25 | 19 | 18097 | 2250 | 29554161 |
Blood triglycerides increased | 31.35 | 16.25 | 39 | 18077 | 12795 | 29543616 |
HIV infection | 31.21 | 16.25 | 15 | 18101 | 1166 | 29555245 |
Developmental hip dysplasia | 30.45 | 16.25 | 10 | 18106 | 281 | 29556130 |
Constipation | 30.41 | 16.25 | 16 | 18100 | 114144 | 29442267 |
Drug-induced liver injury | 29.65 | 16.25 | 50 | 18066 | 21605 | 29534806 |
Hypophosphataemia | 29.51 | 16.25 | 30 | 18086 | 7894 | 29548517 |
Cryptococcosis | 29.33 | 16.25 | 17 | 18099 | 1935 | 29554476 |
Cachexia | 29.22 | 16.25 | 27 | 18089 | 6322 | 29550089 |
Suicidal ideation | 28.94 | 16.25 | 65 | 18051 | 34651 | 29521760 |
Nervous system disorder | 28.56 | 16.25 | 37 | 18079 | 12637 | 29543774 |
Hepatosplenomegaly | 27.94 | 16.25 | 21 | 18095 | 3696 | 29552715 |
Mycobacterium avium complex immune restoration disease | 27.83 | 16.25 | 6 | 18110 | 29 | 29556382 |
Hepatic cirrhosis | 27.73 | 16.25 | 39 | 18077 | 14405 | 29542006 |
Blood lactic acid increased | 27.47 | 16.25 | 25 | 18091 | 5741 | 29550670 |
Hepatomegaly | 27.19 | 16.25 | 31 | 18085 | 9286 | 29547125 |
Genotype drug resistance test positive | 27.05 | 16.25 | 13 | 18103 | 1010 | 29555401 |
Vanishing bile duct syndrome | 26.97 | 16.25 | 11 | 18105 | 577 | 29555834 |
Intracranial pressure increased | 26.89 | 16.25 | 20 | 18096 | 3465 | 29552946 |
Acquired immunodeficiency syndrome | 26.70 | 16.25 | 10 | 18106 | 417 | 29555994 |
Osteonecrosis | 26.69 | 16.25 | 37 | 18079 | 13482 | 29542929 |
Megakaryocytes increased | 26.46 | 16.25 | 6 | 18110 | 38 | 29556373 |
Congenital umbilical hernia | 26.42 | 16.25 | 9 | 18107 | 284 | 29556127 |
Mitochondrial cytopathy | 26.34 | 16.25 | 8 | 18108 | 173 | 29556238 |
Histoplasmosis disseminated | 25.67 | 16.25 | 13 | 18103 | 1131 | 29555280 |
Hepatotoxicity | 25.45 | 16.25 | 42 | 18074 | 17825 | 29538586 |
Blood pressure increased | 25.19 | 16.25 | 7 | 18109 | 73796 | 29482615 |
Psychomotor retardation | 25.05 | 16.25 | 18 | 18098 | 2958 | 29553453 |
Aspartate aminotransferase increased | 25.02 | 16.25 | 87 | 18029 | 59638 | 29496773 |
Infection | 24.89 | 16.25 | 8 | 18108 | 76743 | 29479668 |
Night blindness | 24.77 | 16.25 | 8 | 18108 | 213 | 29556198 |
Hepatitis B | 24.57 | 16.25 | 23 | 18093 | 5474 | 29550937 |
Dyspnoea | 24.53 | 16.25 | 110 | 18006 | 326622 | 29229789 |
Liver transplant | 24.19 | 16.25 | 16 | 18100 | 2300 | 29554111 |
Sickle cell disease | 23.95 | 16.25 | 7 | 18109 | 132 | 29556279 |
Oral candidiasis | 23.69 | 16.25 | 31 | 18085 | 10691 | 29545720 |
Renal tubular dysfunction | 23.40 | 16.25 | 9 | 18107 | 404 | 29556007 |
Toxoplasma serology positive | 23.36 | 16.25 | 4 | 18112 | 3 | 29556408 |
Hepatitis C | 23.26 | 16.25 | 28 | 18088 | 8882 | 29547529 |
Meningitis tuberculous | 23.01 | 16.25 | 10 | 18106 | 615 | 29555796 |
Renal tubular acidosis | 22.67 | 16.25 | 14 | 18102 | 1789 | 29554622 |
Back pain | 22.26 | 16.25 | 18 | 18098 | 102266 | 29454145 |
Nodular regenerative hyperplasia | 22.16 | 16.25 | 10 | 18106 | 673 | 29555738 |
Limb deformity | 21.56 | 16.25 | 9 | 18107 | 501 | 29555910 |
Cytomegalovirus chorioretinitis | 21.51 | 16.25 | 17 | 18099 | 3221 | 29553190 |
Product use issue | 21.48 | 16.25 | 3 | 18113 | 51441 | 29504970 |
Mitochondrial myopathy | 21.31 | 16.25 | 7 | 18109 | 197 | 29556214 |
Synostosis | 21.00 | 16.25 | 6 | 18110 | 104 | 29556307 |
Hypercholesterolaemia | 20.98 | 16.25 | 24 | 18092 | 7214 | 29549197 |
Polyneuropathy chronic | 20.92 | 16.25 | 5 | 18111 | 41 | 29556370 |
Anal cancer | 20.87 | 16.25 | 8 | 18108 | 356 | 29556055 |
Lipohypertrophy | 20.85 | 16.25 | 7 | 18109 | 211 | 29556200 |
Talipes | 20.23 | 16.25 | 13 | 18103 | 1779 | 29554632 |
Gamma-glutamyltransferase increased | 20.02 | 16.25 | 48 | 18068 | 26689 | 29529722 |
Congenital eyelid malformation | 19.95 | 16.25 | 5 | 18111 | 51 | 29556360 |
Glycosuria | 19.83 | 16.25 | 11 | 18105 | 1151 | 29555260 |
Platelet count decreased | 19.73 | 16.25 | 21 | 18095 | 104651 | 29451760 |
Amylase increased | 19.68 | 16.25 | 20 | 18096 | 5260 | 29551151 |
Tubulointerstitial nephritis | 19.36 | 16.25 | 37 | 18079 | 17606 | 29538805 |
Korsakoff's syndrome | 19.20 | 16.25 | 3 | 18113 | 0 | 29556411 |
Osteoporotic fracture | 18.63 | 16.25 | 10 | 18106 | 981 | 29555430 |
Birth mark | 18.46 | 16.25 | 6 | 18110 | 163 | 29556248 |
Nephrolithiasis | 18.45 | 16.25 | 45 | 18071 | 25289 | 29531122 |
Elbow synostosis | 18.44 | 16.25 | 4 | 18112 | 20 | 29556391 |
Liver injury | 18.30 | 16.25 | 30 | 18086 | 12660 | 29543751 |
Neck deformity | 18.30 | 16.25 | 5 | 18111 | 73 | 29556338 |
Subacute sclerosing panencephalitis | 18.28 | 16.25 | 4 | 18112 | 21 | 29556390 |
Nasopharyngitis | 18.00 | 16.25 | 7 | 18109 | 59658 | 29496753 |
Congenital tuberculosis | 17.83 | 16.25 | 4 | 18112 | 24 | 29556387 |
Alanine aminotransferase increased | 17.60 | 16.25 | 88 | 18028 | 70856 | 29485555 |
Trisomy 18 | 17.59 | 16.25 | 6 | 18110 | 190 | 29556221 |
Congenital bowing of long bones | 17.42 | 16.25 | 4 | 18112 | 27 | 29556384 |
Castleman's disease | 17.42 | 16.25 | 4 | 18112 | 27 | 29556384 |
Eyelid ptosis congenital | 17.22 | 16.25 | 5 | 18111 | 92 | 29556319 |
Hepatic function abnormal | 17.14 | 16.25 | 58 | 18058 | 39201 | 29517210 |
Oesophageal candidiasis | 17.10 | 16.25 | 16 | 18100 | 3805 | 29552606 |
Pneumocystis jirovecii pneumonia | 16.97 | 16.25 | 34 | 18082 | 16745 | 29539666 |
Osteomalacia | 16.92 | 16.25 | 9 | 18107 | 867 | 29555544 |
Meconium ileus | 16.83 | 16.25 | 4 | 18112 | 32 | 29556379 |
Protein S deficiency | 16.74 | 16.25 | 5 | 18111 | 102 | 29556309 |
Pulmonary oedema | 16.69 | 16.25 | 3 | 18113 | 42732 | 29513679 |
Fibrous histiocytoma | 16.51 | 16.25 | 5 | 18111 | 107 | 29556304 |
Hydrops foetalis | 16.40 | 16.25 | 6 | 18110 | 234 | 29556177 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Immune reconstitution inflammatory syndrome | 1240.13 | 15.77 | 355 | 20589 | 12115 | 64465673 |
Lipodystrophy acquired | 688.84 | 15.77 | 176 | 20768 | 3851 | 64473937 |
Virologic failure | 674.76 | 15.77 | 168 | 20776 | 3298 | 64474490 |
Depression | 673.95 | 15.77 | 521 | 20423 | 182770 | 64295018 |
Viral mutation identified | 670.55 | 15.77 | 166 | 20778 | 3180 | 64474608 |
Drug interaction | 548.07 | 15.77 | 628 | 20316 | 361455 | 64116333 |
Drug resistance | 494.82 | 15.77 | 237 | 20707 | 34865 | 64442923 |
Abortion spontaneous | 354.91 | 15.77 | 170 | 20774 | 24973 | 64452815 |
Mitochondrial toxicity | 346.31 | 15.77 | 94 | 20850 | 2612 | 64475176 |
Pathogen resistance | 321.20 | 15.77 | 129 | 20815 | 12414 | 64465374 |
Abortion induced | 317.26 | 15.77 | 107 | 20837 | 6281 | 64471507 |
Progressive external ophthalmoplegia | 271.66 | 15.77 | 67 | 20877 | 1260 | 64476528 |
Stillbirth | 246.07 | 15.77 | 77 | 20867 | 3556 | 64474232 |
Blood HIV RNA increased | 215.63 | 15.77 | 57 | 20887 | 1427 | 64476361 |
Maternal exposure during pregnancy | 209.44 | 15.77 | 203 | 20741 | 95681 | 64382107 |
Pregnancy | 206.42 | 15.77 | 111 | 20833 | 20754 | 64457034 |
Pulmonary tuberculosis | 190.61 | 15.77 | 76 | 20868 | 7168 | 64470620 |
Eyelid ptosis | 190.00 | 15.77 | 82 | 20862 | 9443 | 64468345 |
Exposure during pregnancy | 187.80 | 15.77 | 174 | 20770 | 77501 | 64400287 |
CD4 lymphocytes decreased | 162.35 | 15.77 | 51 | 20893 | 2384 | 64475404 |
Loss of personal independence in daily activities | 161.16 | 15.77 | 155 | 20789 | 72299 | 64405489 |
Lipoatrophy | 154.69 | 15.77 | 37 | 20907 | 608 | 64477180 |
Psychiatric decompensation | 133.18 | 15.77 | 44 | 20900 | 2419 | 64475369 |
Retinal toxicity | 128.13 | 15.77 | 37 | 20907 | 1293 | 64476495 |
Fanconi syndrome acquired | 118.00 | 15.77 | 40 | 20904 | 2381 | 64475407 |
Depression suicidal | 117.14 | 15.77 | 40 | 20904 | 2435 | 64475353 |
Viral load increased | 113.06 | 15.77 | 39 | 20905 | 2448 | 64475340 |
Tearfulness | 109.10 | 15.77 | 45 | 20899 | 4628 | 64473160 |
Diplopia | 108.62 | 15.77 | 81 | 20863 | 26684 | 64451104 |
Lactic acidosis | 101.42 | 15.77 | 112 | 20832 | 61298 | 64416490 |
Meningitis cryptococcal | 98.47 | 15.77 | 37 | 20907 | 2972 | 64474816 |
Immune reconstitution inflammatory syndrome associated tuberculosis | 94.92 | 15.77 | 26 | 20918 | 747 | 64477041 |
Caesarean section | 89.70 | 15.77 | 52 | 20892 | 11222 | 64466566 |
Nephropathy toxic | 87.13 | 15.77 | 60 | 20884 | 17454 | 64460334 |
Gynaecomastia | 85.79 | 15.77 | 41 | 20903 | 5975 | 64471813 |
Normal newborn | 85.37 | 15.77 | 40 | 20904 | 5577 | 64472211 |
Paranoia | 83.66 | 15.77 | 57 | 20887 | 16295 | 64461493 |
Pain | 81.62 | 15.77 | 39 | 20905 | 553472 | 63924316 |
Treatment noncompliance | 80.03 | 15.77 | 84 | 20860 | 43398 | 64434390 |
Portal hypertension | 78.52 | 15.77 | 39 | 20905 | 6180 | 64471608 |
Tuberculosis | 77.73 | 15.77 | 50 | 20894 | 12988 | 64464800 |
Multiple-drug resistance | 76.88 | 15.77 | 39 | 20905 | 6463 | 64471325 |
Hepatic fibrosis | 76.63 | 15.77 | 37 | 20907 | 5515 | 64472273 |
Abnormal dreams | 75.13 | 15.77 | 45 | 20899 | 10311 | 64467477 |
Pregnancy on contraceptive | 71.75 | 15.77 | 21 | 20923 | 770 | 64477018 |
HIV-associated neurocognitive disorder | 69.45 | 15.77 | 17 | 20927 | 309 | 64477479 |
Fanconi syndrome | 68.44 | 15.77 | 27 | 20917 | 2474 | 64475314 |
Renal tubular disorder | 68.14 | 15.77 | 35 | 20909 | 5952 | 64471836 |
Live birth | 66.87 | 15.77 | 43 | 20901 | 11161 | 64466627 |
Hyperlipidaemia | 66.42 | 15.77 | 57 | 20887 | 22919 | 64454869 |
Hepatomegaly | 63.86 | 15.77 | 49 | 20895 | 16833 | 64460955 |
Hyperlactacidaemia | 63.01 | 15.77 | 31 | 20913 | 4813 | 64472975 |
Ophthalmoplegia | 63.00 | 15.77 | 26 | 20918 | 2676 | 64475112 |
Lymph node tuberculosis | 59.49 | 15.77 | 19 | 20925 | 937 | 64476851 |
Psychotic disorder | 58.68 | 15.77 | 64 | 20880 | 34514 | 64443274 |
Nightmare | 56.49 | 15.77 | 50 | 20894 | 20943 | 64456845 |
Pregnancy with implant contraceptive | 55.27 | 15.77 | 20 | 20924 | 1444 | 64476344 |
Off label use | 54.30 | 15.77 | 76 | 20868 | 632730 | 63845058 |
Psychomotor skills impaired | 54.20 | 15.77 | 26 | 20918 | 3819 | 64473969 |
Mycobacterium avium complex infection | 53.60 | 15.77 | 26 | 20918 | 3914 | 64473874 |
Lymphadenopathy | 50.80 | 15.77 | 69 | 20875 | 46617 | 64431171 |
Depressive symptom | 50.35 | 15.77 | 26 | 20918 | 4470 | 64473318 |
Hypertriglyceridaemia | 50.17 | 15.77 | 36 | 20908 | 11169 | 64466619 |
Joint swelling | 49.30 | 15.77 | 6 | 20938 | 215376 | 64262412 |
Fatigue | 48.75 | 15.77 | 107 | 20837 | 748623 | 63729165 |
Kaposi's sarcoma | 47.08 | 15.77 | 15 | 20929 | 734 | 64477054 |
Cachexia | 46.84 | 15.77 | 32 | 20912 | 9185 | 64468603 |
Cholestatic liver injury | 46.23 | 15.77 | 23 | 20921 | 3656 | 64474132 |
Drug ineffective | 46.22 | 15.77 | 131 | 20813 | 840116 | 63637672 |
Hepatitis | 46.04 | 15.77 | 65 | 20879 | 45517 | 64432271 |
Nasopharyngitis | 46.03 | 15.77 | 5 | 20939 | 196068 | 64281720 |
Fall | 45.60 | 15.77 | 41 | 20903 | 416785 | 64061003 |
Drug-induced liver injury | 45.28 | 15.77 | 66 | 20878 | 47577 | 64430211 |
Dyslipidaemia | 44.41 | 15.77 | 31 | 20913 | 9211 | 64468577 |
Hepatic cirrhosis | 43.45 | 15.77 | 48 | 20896 | 26250 | 64451538 |
Cytomegalovirus chorioretinitis | 42.68 | 15.77 | 24 | 20920 | 4888 | 64472900 |
Megakaryocytes increased | 42.12 | 15.77 | 9 | 20935 | 86 | 64477702 |
Rheumatoid arthritis | 41.78 | 15.77 | 3 | 20941 | 164291 | 64313497 |
Meningitis tuberculous | 41.28 | 15.77 | 15 | 20929 | 1096 | 64476692 |
Tuberculoid leprosy | 40.64 | 15.77 | 9 | 20935 | 103 | 64477685 |
Anaemia | 39.82 | 15.77 | 234 | 20710 | 378446 | 64099342 |
Ectopic pregnancy | 39.72 | 15.77 | 16 | 20928 | 1548 | 64476240 |
Blood triglycerides increased | 39.34 | 15.77 | 39 | 20905 | 18827 | 64458961 |
Product dose omission issue | 38.77 | 15.77 | 8 | 20936 | 194739 | 64283049 |
Genotype drug resistance test positive | 38.44 | 15.77 | 14 | 20930 | 1030 | 64476758 |
Premature delivery | 37.97 | 15.77 | 38 | 20906 | 18551 | 64459237 |
Hypophosphataemia | 37.51 | 15.77 | 34 | 20910 | 14686 | 64463102 |
Aplasia pure red cell | 37.18 | 15.77 | 25 | 20919 | 6989 | 64470799 |
Cryptococcosis | 36.93 | 15.77 | 18 | 20926 | 2737 | 64475051 |
Night blindness | 36.56 | 15.77 | 11 | 20933 | 444 | 64477344 |
Hypercholesterolaemia | 36.24 | 15.77 | 34 | 20910 | 15339 | 64462449 |
Infection | 35.98 | 15.77 | 8 | 20936 | 184872 | 64292916 |
Renal tubular dysfunction | 35.83 | 15.77 | 12 | 20932 | 688 | 64477100 |
Osteomalacia | 34.53 | 15.77 | 14 | 20930 | 1377 | 64476411 |
Tuberculoma of central nervous system | 34.43 | 15.77 | 11 | 20933 | 543 | 64477245 |
Aspartate aminotransferase increased | 34.36 | 15.77 | 101 | 20843 | 119687 | 64358101 |
Malaria | 34.21 | 15.77 | 10 | 20934 | 365 | 64477423 |
Renal impairment | 33.31 | 15.77 | 108 | 20836 | 134909 | 64342879 |
Disseminated tuberculosis | 32.18 | 15.77 | 18 | 20926 | 3627 | 64474161 |
Hepatotoxicity | 31.81 | 15.77 | 51 | 20893 | 39911 | 64437877 |
Proteinuria | 31.72 | 15.77 | 42 | 20902 | 27681 | 64450107 |
Pain in extremity | 31.71 | 15.77 | 31 | 20913 | 303054 | 64174734 |
Dyspnoea | 31.25 | 15.77 | 124 | 20820 | 718550 | 63759238 |
Sinusitis | 31.18 | 15.77 | 5 | 20939 | 145923 | 64331865 |
Autoimmune hepatitis | 31.16 | 15.77 | 26 | 20918 | 10058 | 64467730 |
Constipation | 30.99 | 15.77 | 18 | 20926 | 229319 | 64248469 |
Pneumonia | 30.85 | 15.77 | 87 | 20857 | 559489 | 63918299 |
Jaundice | 30.82 | 15.77 | 56 | 20888 | 48456 | 64429332 |
Hepatosplenomegaly | 30.64 | 15.77 | 20 | 20924 | 5323 | 64472465 |
Arthralgia | 30.54 | 15.77 | 61 | 20883 | 442199 | 64035589 |
Low density lipoprotein increased | 30.44 | 15.77 | 23 | 20921 | 7717 | 64470071 |
Hepatitis B | 30.43 | 15.77 | 23 | 20921 | 7722 | 64470066 |
Intracranial pressure increased | 30.25 | 15.77 | 22 | 20922 | 6967 | 64470821 |
Extrapulmonary tuberculosis | 29.80 | 15.77 | 9 | 20935 | 368 | 64477420 |
Abdominal discomfort | 29.75 | 15.77 | 11 | 20933 | 182311 | 64295477 |
Nervous system disorder | 29.60 | 15.77 | 37 | 20907 | 23041 | 64454747 |
Nodular regenerative hyperplasia | 29.57 | 15.77 | 11 | 20933 | 859 | 64476929 |
Febrile neutropenia | 29.49 | 15.77 | 12 | 20932 | 187645 | 64290143 |
Mitochondrial cytopathy | 29.43 | 15.77 | 9 | 20935 | 384 | 64477404 |
Oral candidiasis | 29.43 | 15.77 | 37 | 20907 | 23175 | 64454613 |
Back pain | 29.29 | 15.77 | 23 | 20921 | 250148 | 64227640 |
Swelling | 29.09 | 15.77 | 8 | 20936 | 160210 | 64317578 |
Retroviral rebound syndrome | 29.05 | 15.77 | 5 | 20939 | 12 | 64477776 |
Pneumocystis jirovecii pneumonia | 28.78 | 15.77 | 40 | 20904 | 27594 | 64450194 |
Gamma-glutamyltransferase increased | 28.32 | 15.77 | 54 | 20890 | 48456 | 64429332 |
HIV infection | 28.27 | 15.77 | 11 | 20933 | 971 | 64476817 |
Suicidal ideation | 28.24 | 15.77 | 65 | 20879 | 66477 | 64411311 |
Hepatitis fulminant | 27.73 | 15.77 | 20 | 20924 | 6254 | 64471534 |
Pregnancy on oral contraceptive | 27.13 | 15.77 | 10 | 20934 | 761 | 64477027 |
Renal tubular acidosis | 27.09 | 15.77 | 15 | 20929 | 2964 | 64474824 |
Mycobacterium avium complex immune restoration disease | 26.93 | 15.77 | 5 | 20939 | 21 | 64477767 |
Therapeutic product effect decreased | 26.91 | 15.77 | 3 | 20941 | 115348 | 64362440 |
Atrial fibrillation | 26.79 | 15.77 | 11 | 20933 | 171078 | 64306710 |
Neurosyphilis | 26.38 | 15.77 | 5 | 20939 | 24 | 64477764 |
Alanine aminotransferase increased | 26.36 | 15.77 | 102 | 20842 | 138929 | 64338859 |
Gene mutation | 26.11 | 15.77 | 13 | 20931 | 2069 | 64475719 |
Rash maculo-papular | 25.80 | 15.77 | 51 | 20893 | 46975 | 64430813 |
Injection site pain | 25.73 | 15.77 | 3 | 20941 | 111405 | 64366383 |
Vanishing bile duct syndrome | 25.48 | 15.77 | 11 | 20933 | 1266 | 64476522 |
Oesophageal candidiasis | 25.45 | 15.77 | 21 | 20923 | 7996 | 64469792 |
Liver transplant | 25.15 | 15.77 | 16 | 20928 | 4076 | 64473712 |
Cerebral toxoplasmosis | 24.69 | 15.77 | 12 | 20932 | 1814 | 64475974 |
Rash scarlatiniform | 24.68 | 15.77 | 7 | 20937 | 229 | 64477559 |
Hepatic necrosis | 24.44 | 15.77 | 21 | 20923 | 8452 | 64469336 |
Psychomotor retardation | 24.12 | 15.77 | 17 | 20927 | 5126 | 64472662 |
Blood pressure increased | 24.08 | 15.77 | 13 | 20931 | 172539 | 64305249 |
Transaminases increased | 24.03 | 15.77 | 48 | 20896 | 44546 | 64433242 |
Arthropathy | 24.00 | 15.77 | 5 | 20939 | 120962 | 64356826 |
Type III hyperlipidaemia | 23.74 | 15.77 | 4 | 20940 | 8 | 64477780 |
Hypotension | 23.44 | 15.77 | 56 | 20888 | 380918 | 64096870 |
Hepatitis C | 23.39 | 15.77 | 23 | 20921 | 10992 | 64466796 |
Central nervous system immune reconstitution inflammatory response | 23.28 | 15.77 | 5 | 20939 | 49 | 64477739 |
Mitochondrial myopathy | 23.28 | 15.77 | 7 | 20937 | 282 | 64477506 |
Pyrexia | 23.18 | 15.77 | 280 | 20664 | 558364 | 63919424 |
Red blood cell abnormality | 22.81 | 15.77 | 8 | 20936 | 527 | 64477261 |
AIDS related complication | 22.60 | 15.77 | 5 | 20939 | 57 | 64477731 |
Haemophagocytic lymphohistiocytosis | 22.21 | 15.77 | 28 | 20916 | 17581 | 64460207 |
Influenza | 21.99 | 15.77 | 4 | 20940 | 106527 | 64371261 |
CD4 lymphocytes | 21.70 | 15.77 | 4 | 20940 | 16 | 64477772 |
Premature rupture of membranes | 21.43 | 15.77 | 14 | 20930 | 3730 | 64474058 |
Completed suicide | 21.18 | 15.77 | 25 | 20919 | 224389 | 64253399 |
Therapeutic product effect incomplete | 21.11 | 15.77 | 4 | 20940 | 103478 | 64374310 |
Musculoskeletal stiffness | 20.83 | 15.77 | 7 | 20937 | 123199 | 64354589 |
Bronchitis | 20.56 | 15.77 | 5 | 20939 | 108738 | 64369050 |
Acquired immunodeficiency syndrome | 20.55 | 15.77 | 6 | 20938 | 218 | 64477570 |
Glycosuria | 20.40 | 15.77 | 11 | 20933 | 2063 | 64475725 |
Viral load decreased | 20.36 | 15.77 | 4 | 20940 | 24 | 64477764 |
Nausea | 20.24 | 15.77 | 161 | 20783 | 785639 | 63692149 |
Amylase increased | 20.15 | 15.77 | 20 | 20924 | 9665 | 64468123 |
Osteoporosis | 19.98 | 15.77 | 43 | 20901 | 42037 | 64435751 |
Hepatic steatosis | 19.95 | 15.77 | 36 | 20908 | 30971 | 64446817 |
Cerebellar syndrome | 19.94 | 15.77 | 15 | 20929 | 5001 | 64472787 |
Gait disturbance | 19.92 | 15.77 | 16 | 20928 | 172139 | 64305649 |
Hepatic encephalopathy | 19.74 | 15.77 | 29 | 20915 | 21037 | 64456751 |
Granulomatous liver disease | 19.49 | 15.77 | 9 | 20935 | 1213 | 64476575 |
Anaemia macrocytic | 19.39 | 15.77 | 14 | 20930 | 4384 | 64473404 |
Isosporiasis | 19.35 | 15.77 | 5 | 20939 | 114 | 64477674 |
Twin pregnancy | 19.24 | 15.77 | 8 | 20936 | 839 | 64476949 |
Visual field defect | 19.17 | 15.77 | 18 | 20926 | 8128 | 64469660 |
Blood lactic acid increased | 18.96 | 15.77 | 20 | 20924 | 10381 | 64467407 |
Weight increased | 18.84 | 15.77 | 25 | 20919 | 213323 | 64264465 |
Subacute sclerosing panencephalitis | 18.84 | 15.77 | 4 | 20940 | 37 | 64477751 |
Tubulointerstitial nephritis | 18.77 | 15.77 | 35 | 20909 | 30874 | 64446914 |
Blood alkaline phosphatase increased | 18.62 | 15.77 | 50 | 20894 | 56229 | 64421559 |
Hypertrophic cardiomyopathy | 18.54 | 15.77 | 10 | 20934 | 1876 | 64475912 |
CSF HIV escape syndrome | 18.35 | 15.77 | 6 | 20938 | 319 | 64477469 |
Cushingoid | 18.28 | 15.77 | 17 | 20927 | 7586 | 64470202 |
Toxoplasma serology positive | 18.12 | 15.77 | 4 | 20940 | 45 | 64477743 |
Acquired gene mutation | 18.06 | 15.77 | 10 | 20934 | 1976 | 64475812 |
Histoplasmosis disseminated | 18.00 | 15.77 | 10 | 20934 | 1988 | 64475800 |
Inappropriate schedule of product administration | 17.93 | 15.77 | 4 | 20940 | 92282 | 64385506 |
Antiviral drug level above therapeutic | 17.89 | 15.77 | 4 | 20940 | 48 | 64477740 |
Opportunistic infection | 17.85 | 15.77 | 11 | 20933 | 2651 | 64475137 |
Foetal death | 17.72 | 15.77 | 15 | 20929 | 5915 | 64471873 |
Oropharyngeal candidiasis | 17.65 | 15.77 | 9 | 20935 | 1506 | 64476282 |
Encephalitis | 17.49 | 15.77 | 21 | 20923 | 12550 | 64465238 |
Folate deficiency | 17.47 | 15.77 | 11 | 20933 | 2752 | 64475036 |
Stevens-Johnson syndrome | 17.42 | 15.77 | 36 | 20908 | 34213 | 64443575 |
Hepatic function abnormal | 17.27 | 15.77 | 53 | 20891 | 64260 | 64413528 |
Liver disorder | 17.25 | 15.77 | 47 | 20897 | 53304 | 64424484 |
Splenomegaly | 17.23 | 15.77 | 25 | 20919 | 17936 | 64459852 |
Osteonecrosis | 17.19 | 15.77 | 32 | 20912 | 28197 | 64449591 |
Acute stress disorder | 17.08 | 15.77 | 6 | 20938 | 397 | 64477391 |
Myelitis transverse | 17.07 | 15.77 | 9 | 20935 | 1614 | 64476174 |
Drug abuse | 17.02 | 15.77 | 11 | 20933 | 132363 | 64345425 |
Nephrolithiasis | 16.72 | 15.77 | 41 | 20903 | 43642 | 64434146 |
Drug intolerance | 16.63 | 15.77 | 22 | 20922 | 187970 | 64289818 |
Viraemia | 16.50 | 15.77 | 10 | 20934 | 2339 | 64475449 |
Colour vision tests abnormal | 16.27 | 15.77 | 3 | 20941 | 12 | 64477776 |
Abdominal pain upper | 15.98 | 15.77 | 20 | 20924 | 175010 | 64302778 |
Fat tissue increased | 15.97 | 15.77 | 7 | 20937 | 836 | 64476952 |
Urinary tract infection | 15.91 | 15.77 | 32 | 20912 | 231564 | 64246224 |
Pancreatitis | 15.89 | 15.77 | 49 | 20895 | 59558 | 64418230 |
None
Source | Code | Description |
---|---|---|
ATC | J05AG03 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Non-nucleoside reverse transcriptase inhibitors |
ATC | J05AR06 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations |
ATC | J05AR11 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Antivirals for treatment of HIV infections, combinations |
FDA MoA | N0000009948 | Non-Nucleoside Reverse Transcriptase Inhibitors |
FDA EXT | N0000175460 | Non-Nucleoside Analog |
FDA EPC | N0000175463 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000998 | Antiviral Agents |
MeSH PA | D065695 | Cytochrome P-450 CYP2B6 Inducers |
MeSH PA | D065689 | Cytochrome P-450 CYP2C19 Inhibitors |
MeSH PA | D065688 | Cytochrome P-450 CYP2C9 Inhibitors |
MeSH PA | D065701 | Cytochrome P-450 CYP3A Inducers |
MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D065606 | Metabolic Side Effects of Drugs and Substances |
MeSH PA | D019384 | Nucleic Acid Synthesis Inhibitors |
MeSH PA | D018894 | Reverse Transcriptase Inhibitors |
FDA MoA | N0000182140 | Cytochrome P450 2C19 Inhibitors |
FDA MoA | N0000182141 | Cytochrome P450 3A4 Inhibitors |
FDA MoA | N0000185504 | Cytochrome P450 2C9 Inhibitors |
FDA MoA | N0000187064 | Cytochrome P450 2B6 Inducers |
FDA MoA | N0000190118 | Cytochrome P450 3A Inducers |
CHEBI has role | CHEBI:36044 | antiviral drugs |
CHEBI has role | CHEBI:53756 | reverse transcriptase inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Human immunodeficiency virus infection | indication | 86406008 | DOID:526 |
Prevention of HIV Infection after Exposure | off-label use | ||
Osteomalacia | contraindication | 4598005 | DOID:10573 |
Hypophosphatemia | contraindication | 4996001 | |
Suicidal thoughts | contraindication | 6471006 | |
Hypercholesterolemia | contraindication | 13644009 | |
Depressive disorder | contraindication | 35489007 | |
Fanconi syndrome | contraindication | 40488004 | DOID:1062 |
Acute nephropathy | contraindication | 58574008 | |
Hepatic failure | contraindication | 59927004 | |
Aggressive behavior | contraindication | 61372001 | |
Chronic type B viral hepatitis | contraindication | 61977001 | |
Kidney disease | contraindication | 90708001 | DOID:557 |
Lactic acidosis | contraindication | 91273001 | DOID:3650 |
Chronic hepatitis C | contraindication | 128302006 | |
Seizure disorder | contraindication | 128613002 | |
Liver function tests abnormal | contraindication | 166603001 | |
Paranoid disorder | contraindication | 191667009 | |
Steatosis of liver | contraindication | 197321007 | |
Mania | contraindication | 231494001 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Pathological fracture | contraindication | 268029009 | |
Pregnancy, function | contraindication | 289908002 | |
Hypertriglyceridemia | contraindication | 302870006 | |
Osteopenia | contraindication | 312894000 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Obesity | contraindication | 414916001 | DOID:9970 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 10.6 | acidic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
600MG;200MG;300MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 8592397 | Jan. 13, 2024 | TREATMENT OF HIV-1 INFECTION IN ADULTS |
600MG;200MG;300MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 8592397 | Jan. 13, 2024 | TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
600MG;200MG;300MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 8716264 | Jan. 13, 2024 | TREATMENT OF HIV INFECTION |
600MG;200MG;300MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 9457036 | Jan. 13, 2024 | TREATMENT OF HIV INFECTION |
600MG;200MG;300MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 9744181 | Jan. 13, 2024 | TREATMENT OF HIV INFECTION |
600MG;200MG;300MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 9018192 | June 13, 2026 | TREATMENT OF HIV-1 INFECTION IN ADULTS |
600MG;200MG;300MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 9018192 | June 13, 2026 | TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
600MG;200MG;300MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 9545414 | June 13, 2026 | TREATMENT OF HIV-1 INFECTION IN ADULTS |
600MG;200MG;300MG | ATRIPLA | GILEAD SCIENCES | N021937 | July 12, 2006 | RX | TABLET | ORAL | 9545414 | June 13, 2026 | TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Nuclear receptor subfamily 1 group I member 2 | Nuclear hormone receptor | WOMBAT-PK | |||||||
Cholesterol 24-hydroxylase | Enzyme | Kd | 6.10 | CHEMBL | |||||
Cytochrome P450 3A4 | Enzyme | INHIBITOR | IC50 | 4.76 | IUPHAR | ||||
Reverse transcriptase/RNaseH | Enzyme | INHIBITOR | Ki | 8.52 | CHEMBL | CHEMBL | |||
Gag-Pol polyprotein | Polyprotein | INHIBITOR | IC50 | 8.30 | WOMBAT-PK | ||||
Reverse transcriptase | Enzyme | IC50 | 8.89 | CHEMBL | |||||
Reverse transcriptase protein | Unclassified | Ki | 8.07 | CHEMBL | |||||
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120 | Unclassified | IC50 | 8.46 | CHEMBL |
ID | Source |
---|---|
4021133 | VUID |
N0000148587 | NUI |
D00896 | KEGG_DRUG |
4021133 | VANDF |
C0674428 | UMLSCUI |
CHEBI:119486 | CHEBI |
EFZ | PDB_CHEM_ID |
CHEMBL223228 | ChEMBL_ID |
DB00625 | DRUGBANK_ID |
C098320 | MESH_SUPPLEMENTAL_RECORD_UI |
64139 | PUBCHEM_CID |
11287 | IUPHAR_LIGAND_ID |
7718 | INN_ID |
JE6H2O27P8 | UNII |
195084 | RXNORM |
11884 | MMSL |
210786 | MMSL |
7492 | MMSL |
d04355 | MMSL |
007651 | NDDF |
116078005 | SNOMEDCT_US |
387001004 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
SUSTIVA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0056-0470 | CAPSULE, GELATIN COATED | 50 mg | ORAL | NDA | 31 sections |
SUSTIVA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0056-0474 | CAPSULE, GELATIN COATED | 200 mg | ORAL | NDA | 31 sections |
SUSTIVA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0056-0510 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 31 sections |
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0093-5234 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 30 sections |
Efavirenz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-2233 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 26 sections |
Atripla | HUMAN PRESCRIPTION DRUG LABEL | 3 | 15584-0101 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 34 sections |
Efavirenz | Human Prescription Drug Label | 1 | 31722-504 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 28 sections |
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate | Human Prescription Drug Label | 3 | 33342-138 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 30 sections |
Efavirenz, emtricitabine and tenofovir disoproxil fumarate | Human Prescription Drug Label | 3 | 42385-915 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 30 sections |
Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate | Human Prescription Drug Label | 3 | 42385-928 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 30 sections |
Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate | Human Prescription Drug Label | 3 | 42385-929 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 30 sections |
Efavirenz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42543-889 | TABLET | 600 mg | ORAL | ANDA | 26 sections |
SYMFI LO | HUMAN PRESCRIPTION DRUG LABEL | 3 | 49502-425 | TABLET, FILM COATED | 400 mg | ORAL | NDA | 32 sections |
SYMFI | HUMAN PRESCRIPTION DRUG LABEL | 3 | 49502-475 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 31 sections |
Efavirenz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-382 | TABLET | 600 mg | ORAL | ANDA | 26 sections |
Atripla | HUMAN PRESCRIPTION DRUG LABEL | 3 | 53808-0208 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 31 sections |
SUSTIVA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4668 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 29 sections |
Atripla | HUMAN PRESCRIPTION DRUG LABEL | 3 | 54868-5643 | TABLET, FILM COATED | 600 mg | ORAL | NDA | 31 sections |
Atripla Access | HUMAN PRESCRIPTION DRUG LABEL | 3 | 61958-1601 | TABLET, FILM COATED | 600 mg | ORAL | EXPORT ONLY | 34 sections |
Efavirenz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64380-889 | TABLET | 600 mg | ORAL | ANDA | 18 sections |
Efavirenz | Human Prescription Drug Label | 1 | 64980-406 | CAPSULE | 50 mg | ORAL | ANDA | 29 sections |
Efavirenz | Human Prescription Drug Label | 1 | 64980-407 | CAPSULE | 200 mg | ORAL | ANDA | 29 sections |
Efavirenz | Human Prescription Drug Label | 1 | 65862-049 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 28 sections |
Efavirenz | Human Prescription Drug Label | 1 | 65862-104 | CAPSULE | 50 mg | ORAL | ANDA | 29 sections |
Efavirenz | Human Prescription Drug Label | 1 | 65862-104 | CAPSULE | 50 mg | ORAL | ANDA | 29 sections |
Efavirenz | Human Prescription Drug Label | 1 | 65862-105 | CAPSULE | 100 mg | ORAL | ANDA | 29 sections |
Efavirenz | Human Prescription Drug Label | 1 | 65862-105 | CAPSULE | 100 mg | ORAL | ANDA | 29 sections |
Efavirenz | Human Prescription Drug Label | 1 | 65862-106 | CAPSULE | 200 mg | ORAL | ANDA | 29 sections |
Efavirenz | Human Prescription Drug Label | 1 | 65862-106 | CAPSULE | 200 mg | ORAL | ANDA | 29 sections |
Efavirenz, Emtricitabine And Tenofovir Disoproxil Fumarate | Human Prescription Drug Label | 3 | 65862-497 | TABLET, FILM COATED | 600 mg | ORAL | ANDA | 30 sections |